Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
Allarity Therapeutics(US:ALLR) Globenewswire·2025-05-12 12:00LinkedIn: https://www.linkedin.com/company/allaritytx/ TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company's CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company's DRP companion diagnostic platform and conduct one-on-one meetings at the Pharma Partne ...